Key updates in clinical guidelines for the management of patients with chronic heart failure

Chronic heart failure (CHF) is an increasingly important issue in the context of global population aging and advances in health care. This article analyzes key updates in the clinical guidelines of the European Society of Cardiology and the Russian Society of Cardiology for the management of patients with CHF, including revised classification and therapeutic approaches. A systematic search was conducted in PubMed, Google Scholar, and eLibrary.ru. The new classification emphasizes prevention of CHF rather than solely focusing on therapeutic strategies for established disease. The article discusses the roles of sodium–glucose cotransporter 2 inhibitors, angiotensin receptor–neprilysin inhibitors, and highlights the novel mineralocorticoid receptor antagonist finerenone. A synthesis of recent studies and expert opinions provides clinicians with current evidence-based knowledge on the management of CHF. The most important aspect of the updated recommendations is the preventive approach aimed at reducing CHF incidence. These data may be useful for primary care physicians, hospital-based clinicians, and clinical researchers, contributing to improved quality and outcomes of patient care.